Wegovy (semaglutide) is a medication that belongs to a class of drugs called GLP-1 receptor agonists. It is a once-weekly injectable medication used to improve blood sugar control in adults with type 2 diabetes. Wegovy works by mimicking the actions of the hormone GLP-1, which helps regulate glucose metabolism and appetite. It promotes insulin secretion, slows gastric emptying, and decreases glucagon secretion, leading to lower blood sugar levels. Additionally, Wegovy is also approved as an adjunct to diet and exercise for the treatment of obesity, in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity.